What 1,656 Real-World Cannabis Dose Events Tell Us About Patient Outcomes

An Australian real-world evidence study tracked 317 medical cannabis patients dose by dose, finding nearly half achieved clinically meaningful pain relief. Here is what the data reveals and why it matters for clinicians, regulators, and patients navigating an evidence gap.

The Evidence Gap in Australian Medical Cannabis

More than one million medicinal cannabis prescriptions have been issued in Australia through the Therapeutic Goods Administration's Special Access Scheme (SAS-B) and Authorised Prescriber pathways. More than 700,000 Australians reported using cannabis for therapeutic reasons in the past year. Yet the clinical guidance available to prescribers remains largely confined to the principle of "start low and go slow."

Clinicians operating under this framework lack structured benchmarks for dosing timelines, formulation selection, expected adverse effect profiles, or clear review points. This is the evidence gap that the From Data to Decision-Making whitepaper, published in September 2025 by The Health Collective, powered by OnTracka, sets out to begin filling.

Study Design and Methodology

This analysis is built on 1,656 individual dose events recorded by 317 participants actively using medical cannabis as part of their treatment. Data was collected in real time through the OnTracka mobile application, specifically via the OnTracka Dosing Diary (PrecisionDose).

How each dose event was captured

Each dose event followed a consistent four-step protocol:

1. Dose recorded: product/brand, dose quantity, and route of administration verified at point of dosing

2. Baseline symptoms: participants rated current symptoms (pain, fatigue, nausea, depression) on a Visual Analogue Scale (VAS) from 1 (none) to 10 (worst) before taking their medicine

3. Post-dose re-scoring: once effects were felt, participants re-rated the same symptoms; pre-dose scores were hidden to reduce reporting bias

4. Experience rating and adverse effects: a 1–5 global experience rating was recorded alongside any adverse effects from a structured list (dizziness, sedation, cognitive fog, dry mouth, euphoria)

   
   

For inhaled products, participants followed the Foltin Puff Procedure (Chait, Corwin & Johanson, 1988), a validated standardised inhalation protocol. For oral or rectal products (oils, pastilles, suppositories), baseline scores were recorded first and participants returned when they noticed the medicine taking effect.

Viewed in sequence, these individual entries formed a treatment timeline making it possible to observe not just whether outcomes shifted, but when, for whom, and under what formulation conditions.

Statistical approach

Random Forest regression was used to identify consistent associations between formulation types and symptom responses. Meaningful improvement was defined using two clinically established thresholds drawn from IMMPACT recommendations (Dworkin et al., 2009):

• R20 - a 20% or greater improvement from baseline (noticeable, moderate benefit)

• R50 - a 50% or greater improvement from baseline (strong, clinically meaningful change)

Ethics and data integrity

All data cleansing and validity checks were conducted under formal human research ethics approval from the University of Sydney Human Research Ethics Committee (2021–2023). An exemption from further ethics review was granted by Western Sydney University Human Ethics Committee in July 2024 (H16133). Participant authenticity was verified through proprietary validation methods, with preference given to participants enrolled in formal real-world data studies where legal status as authorised Australian medical cannabis patients was confirmed.

Academic oversight was provided by Associate Professor Mike Armour, NICM Health Research Institute, Western Sydney University, a researcher with over 110 publications whose work includes multiple clinical studies on medicinal cannabis, endometriosis, and women's health.

What the Data Shows

Symptom response rates

Pain showed the strongest overall response to cannabis treatment across the dataset.

The adverse effect timeline

Many participants experienced a brief worsening of symptoms, particularly pain or fatigue, between doses three and five. This appears to reflect early sedative or psychoactive effects before dosing was optimised, and resolved with continued use.

Formulation-symptom associations

Random Forest regression analysis identified distinct associations between product composition and symptom changes. These are observational associations, not evidence of causation:

Clinical Implications: Five Points for Health Professionals

The research team including A/Prof Mike Armour, pharmacognosist Justin Sinclair, and pharmacoeconomist Mark Gannott identified five key operational messages for clinicians:

1. Improvements take weeks, not days. Consistent benefits were most evident between doses 20 and 40. Patients should be counselled that relief is not always immediate.

2. Symptoms may temporarily worsen early. Particularly between doses 3 and 5, as the body adjusts to early titration.

3. Close monitoring in the first weeks is essential. This is when adverse effects are most common and dose titration is underway.

4. Dose 10 is a natural clinical review point. By this stage, most transient adverse effects have resolved; persistent effects may indicate a need to adjust formulation, route, or timing.

5. Doses 20–40 represent the optimal review window. This is when progress is most meaningfully assessable, and continuation, switching, or deprescribing decisions should be considered.

Industry and Regulatory Context

This study represents a structurally novel contribution to the Australian medical cannabis evidence base. Unlike randomised controlled trials, which are costly, time-intensive, and struggle to capture the complexity of real-world prescribing, this dose-sequenced real-world dataset captures outcomes at the symptom level rather than through broad diagnosis categories.

It does not attempt to replace RCTs. Instead, as A/Prof Armour notes in the foreword, it performs a complementary function: identifying what works in community settings, informing more targeted trial design, and providing clinicians with practical guidance on when side effects are likely to appear and when benefits are most likely to emerge.

At a time when the TGA is under scrutiny and prescribers operate largely without structured dosing benchmarks, this validated benchmark set offers review anchors, outcome thresholds, and formulation associations grounded in over 1.2 million real-world data points captured through the OnTracka platform.

What Comes Next

The September 2025 paper is the first in a planned series. The second publication will focus on dose-response patterns at anchor doses 5, 10, 20, and 40, examining how dosing ranges align with symptom changes and adverse effects across different patient populations.

Condition-specific analyses are also underway, with planned publications focusing on endometriosis, chronic pelvic pain, menopause, and gastrointestinal conditions — populations with overlapping symptoms (pain, fatigue, nausea, mood disturbance) that are highly represented in the current dataset.

Important note on interpretation: This analysis is observational and dose-sequenced, not a randomised controlled trial. Associations between formulation types and symptom changes do not imply causation. Results represent participant-reported outcomes and should be interpreted as real-world evidence informing clinical practice and research design, not as clinical recommendations. Individual responses will vary.

How to Cite This Research

For research collaboration enquiries, contact Mark Gannott (Lead Author, CEO, Rogue Insights and Solutions; Adjunct Fellow, NICM Health Research Institute, Western Sydney University) or A/Prof Mike Armour (Academic Lead, NICM Health Research Institute, Western Sydney University).

About OnTracka

OnTracka is an advanced data collection platform that captures standardised real-world medical cannabis data, supports clinical trials, and monitors safety and outcomes with scientific rigour. Founded by Chad Walkaden, a Stage IV cancer survivor, OnTracka has generated more than 1.2 million real-world data points shared with researchers at The Health Collective. All data is collected with patient consent and in compliance with Australia's privacy laws, in collaboration with leading universities and ethics bodies.

---

Keywords for research discovery: medical cannabis real-world evidence Australia · OnTracka PrecisionDose · participant-reported outcomes cannabis · TGA SAS medicinal cannabis data · cannabis pain reduction R20 R50 · CBD THC formulation outcomes · tolerability checkpoint dose 10 · adverse effects medical cannabis timeline · dose-sequenced cannabis data · The Health Collective whitepaper 2025 · NICM Western Sydney University cannabis research · random forest cannabis symptom analysis